首页> 外文期刊>Asian Journal of Urology >Pretreatment neutrophil-to-lymphocyte ratio predicts worse survival outcomes and advanced tumor staging in patients undergoing radical cystectomy for bladder cancer
【24h】

Pretreatment neutrophil-to-lymphocyte ratio predicts worse survival outcomes and advanced tumor staging in patients undergoing radical cystectomy for bladder cancer

机译:预处理中性白细胞与淋巴细胞的比率预测了接受膀胱癌根治性膀胱切除术的患者的生存结果较差,肿瘤分期提前

获取原文
       

摘要

Objective To determine the role of neutrophil-to-lymphocyte ratio (NLR) in prognosticating survival outcomes in patients with advanced/metastatic urothelial bladder cancer. Methods We retrospectively reviewed 84 patients undergoing radical cystectomy (RC) for UCB from January 2002 to June 2012. NLR was computed (median: 5 days) prior to surgery. No patients received neoadjuvant chemotherapy. NLR was analyzed as a continuous variable and a cut-off point of 2.7 was obtained, with a statistical receiver operating characteristics of 0.74. Kaplan–Meier curves, multivariate Cox proportional hazard and logistics regression models were used to predict NLR association with survival outcomes. Results The median follow-up period was 30.1 months (range: 3.2–161.7) owing to high recurrence rate and subsequent mortalities, compared to the median 64.7 months in patients alive at the end of study period. NLR ≥2.7 was associated with worse survival outcomes (5-year disease-specific survival: 22% vs 58%, p ?=?0.017, 95%CI: 1.193–6.009; 5-year overall survival: 23% vs 60%, p ?=?0.008, 95%CI: 1.322–6.147). Furthermore, on multivariate analyses, higher NLR was independently associated with higher recurrence rate ( p ?=?0.007, HR =6.999, 95%CI: 1.712–28.606), higher T staging ( p ?=?0.021, HR?=?3.479, 95%CI: 1.212–9.990) and lymph node involvement ( p ?=?0.009, HR?=?4.534, 95%CI: 1.465–14.034). Conclusion This study suggests that NLR can be an inexpensive novel factor for patients risk stratification pre-operatively. This improves patient counseling and identifies patients who may benefit from multimodal treatment.
机译:目的探讨中性粒细胞与淋巴细胞比(NLR)在晚期/转移性尿路上皮膀胱癌患者预后中的作用。方法我们回顾性回顾了2002年1月至2012年6月接受根治性膀胱切除术(RC)的84例UCB患者的临床资料。术前计算了NLR(中位数:5天)。没有患者接受新辅助化疗。将NLR作为连续变量进行分析,得出的截止点为2.7,统计接收器的工作特性为0.74。 Kaplan–Meier曲线,多元Cox比例风险和物流回归模型用于预测NLR与生存结果的关联。结果由于较高的复发率和随后的死亡率,中位随访期为30.1个月(范围:3.2–161.7),而研究期末活着患者的中位随访期为64.7个月。 NLR≥2.7与较差的生存结果相关(5年特定疾病生存率:22%vs 58%,p?=?0.017,95%CI:1.193–6.009; 5年总生存期:23%vs 60%, p?= 0.008,95%CI:1.322–6.147)。此外,在多变量分析中,较高的NLR独立地与较高的复发率相关(p = 0.007,HR = 6.999,95%CI:1.712–28.606),T分期较高(p = 0.021,HR = 3.479)。 ,95%CI:1.212–9.990)和淋巴结受累(p == 0.009,HR == 4.534,95%CI:1.465–14.034)。结论这项研究表明,NLR可以作为患者术前危险分层的廉价新因素。这改善了患者咨询并确定了可能从多模式治疗中受益的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号